INCOMIN Data Showing Superior Efficacy of Betaferon(R)/Betaseron(R) Versus Avonex(R)

"These results from the independent INCOMIN study clearly suggest that treatment of Multiple Sclerosis should begin with a regimen of high dose, high frequency treatment such as Betaferon(R)/Betaseron(R) rather than lower-dose, less-frequent regimens," said Dr Hubertus Erlen, Chairman of the Board of Executive Directors of Schering AG. "They also confirm the results of previous studies which have shown the need for aggressive and early treatment to counter the progression of the disease. We will ensure these findings are broadly communicated in all markets, in particular in the US."

In the two-year prospective study, 188 patients with relapsing-remitting Multiple Sclerosis were randomized to receive either interferon beta-1b or interferon beta-1a. Over two years, 51% of individuals administered interferon beta-1b remained relapse-free compared to 36% given interferon beta-1a; this means a 42 % increased probability that Betaferon(R)/Betaseron(R) treated patients would remain relapse-free. Furthermore, 55% of patients receiving Interferon beta-1b compared with 26% on Interferon beta-1a remained free from new brain lesions at the MRI assessment.

Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Fertility Control & Hormone Therapy, Diagnostics & Radiopharmaceuticals, Dermatology as well as Specialized Therapeutics for disabling diseases in the fields of the central nervous system, oncology and cardiovascular. As a global player with innovative products, Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life.

your contacts:

Oliver Renner Business Communication office: +49-30-468-12-431 oliver.renner@schering.de

Peter Vogt Investor Relations office: +49-30-468-12838 peter.vogt@schering.de

Claudia Schmitt Pharma Communication office: +49-30-468-15805 claudia.schmitt@schering.de

In the US: Jeanine O'Kane Media Relations Tel: +1-973-487-2095

Joanne Marion Investor Relations +1-973-487-2164

Find additional information at: http://www.schering.de/eng

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Schering AG's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Certain factors that may cause such differences are discussed in our Form 20-F and Form 6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

Source: Schering AG

Contact: Oliver Renner, Business Communication, office, +49-30-468-12-431, oliver.renner@schering.de, or Peter Vogt, Investor Relations, office, +49-30-468-12838, peter.vogt@schering.de, or Claudia Schmitt, Pharma Communication, office, +49-30-468-15805, claudia.schmitt@schering.de, or U.S. -- , Jeanine O'Kane, Media Relations, +1-973-487-2095, or Joanne Marion, Investor Relations, +1-973-487-2164, all of Schering AG Website: http://www.schering.de/eng Company News On-Call: http://www.prnewswire.com/comp/160170.html